Candel Therapeutics Inc

NASDAQ:CADL  
3.16
-0.39 (-10.99%)
Products, Regulatory

Candel Therapeutics Announces Release Of Initial Data On Can-2409

Published: 05/26/2022 23:41 GMT
Candel Therapeutics Inc (CADL) - Candel Therapeutics Announces Release of Initial Data on Can-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients With Non-small Cell Lung Cancer.
Candel Therapeutics Inc - Evidence of Tumor Regression in Both Injected and Uninjected Lesions With Can-2409.
Candel Therapeutics Inc - Induction of Local and Systemic Cytotoxic T Cell Response After Experimental Treatment With Can-2409.